Brevibacterium paucivorans bacteremia: case report and review of the literature

Nobuhiro Asai 1,2, Hiroyuki Suematsu 2, Atsuko Yamada 2, Hiroki Watanabe 1,2, Naoya Nishiyama 1,2, Daisuke Sakanashi 2, Hideo Kato 2, Arufumi Shiota 2, Mao Hagihara 2, Yusuke Koizumi 1,2, Yuka Yamagishi 1,2 and Hiroshige Mikamo 1,2*

Abstract

Background: Brevibacteria are obligate aerobic gram-positive rods that are associated with milk products and are also found on human skin. Brevibacterium has been reported as a rare cause of catheter related blood steam infection mainly in immunocompromised hosts such as malignancies or AIDS patients.

Case presentation: A 94-year old woman, which had a past history of diabetes mellitus and chronic heart failure, presented with high fever associated with decreased oral intake and appetite loss and was admitted to our institute. A physical examination at the time of presentation was unremarkable. On day 2, both blood cultures collected on admission became positive with coryneform organism within 24 h without Staphylococci and Brevibacterium species were identified by Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Subsequently, genetic investigation by 16S ribosomal RNA analysis was performed in order to identify the organism. Finally, the result identified this pathogen as Brevibacterium paucivorans with 99.5% homology on the Ez taxon database. The patient was started empirically on meropenem and teicoplanin for broad-spectrum antibiotic coverage. The patient’s fever finally abated and labs were also improved. On day 14, the antibiotic therapy was discontinued. The site of infections was unknown. We hereby report a case of Brevibacterium paucivorans bacteremia in an immunocompetent patient and review cases of B. species bacteremia previously reported. This is the first case of B. paucivorans bacteremia as far as we could search.

Conclusion: Physicians and microbiologists should be aware that Brevibacteria are uncommon but important agents which could cause opportunistic infections in immunocompetent.

Keywords: Brevibacterium paucivorans, Compromised host, Bacteremia, Immunocompetent
normal range as shown in supplementary file. Two sets of blood cultures for aerobic and anaerobic bacteria, mycobacteria and fungi were drawn. Then, the patient was started empirically on meropenem and teicoplanin for broad-spectrum antibiotic coverage. In addition to blood cultures, a urinalysis with culture and a chest X-ray and CT were performed and found to be normal. The patient had no clinically evident sites of infection by history or physical examination. On day 2, a coryneform organism was recovered for 32 h by BACTEC (BD, Tokyo, Japan) from both the aerobic and anaerobic tubes of all blood cultures. *Brevibacterium* species were identified by Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The score value was 2.36. On gram-stained smears from the culture plates, the organisms appeared as Gram-positive, club-shaped, slightly curved rods, and some coccal forms were present (Fig. 1a). The bacteria were subcultured on Trypticase Soy Agar II with 5% Sheep Blood (BD, Tokyo, Japan) at 35 °C in 5% CO₂, which resulted in a gray-white, smooth, non-hemolytic colonies after a 48-incubation (Fig. 1b). Subsequently, genetic investigation by 16S rRNA analysis was performed in order to identify the organism. Finally, the result identified this pathogen as *Brevibacterium paucivorans* with 99.5% homology on the Ez taxon database (http://www.ezbiocloud.net/eztaxon).

For comparison of a hydrolysis of casein in the organism, we obtained a type strain of *B. casei*, JCM 2594^T^ and of *B. paucivorans*, JCM 11567^T^, from the Japan Collection of Microorganisms (JCM). Pyrazinamidase test was performed using PZA broth (Kyokuto Pharmaceutical Inc., Tokyo, Japan) according to the Clinical and Laboratory Standards Institute guidelines [4]. The isolate was susceptible to gentamicin [minimum inhibitory concentration (MIC) = 1 μg/ml], ciprofloxacin (MIC = 0.25 μg/ml), vancomycin (MIC≤0.5 μg/ml), meropenem (MIC≤0.5 μg/ml) and rifampicin (MIC≤0.12 μg/ml), and was resistant to clindamycin (MIC> 4 μg/ml), and was immediately resistant to ceftriaxone (MIC = 2 μg/ml), and cefepim (MIC = 2 μg/ml) as shown in Table 1.

**Discussion**

*Brevisbacterium* species are gram-positive, irregular, slender, rod-shaped, non-acid fast bacteria which resemble corynebacteria. At the present time, ten species are classified in this genus: *B. linens*, *B. iodinum*, *B. epidermidis*, *B. casei*, *B. mcbrellneri*, *B. otitidis*, *B. avium*, *B. paucivorans*, *B. luteolum* and *B. sanguinis* [4–7]. The main habitats of *Brevisbacterium* sp. are dairy products, where the bacteria contribute to the aroma and color. They are also found on human skin surfaces, genital hair and otorrhea [6, 8, 9]. Twelve bacteremia cases caused by

**Fig. 1** showed (a) blood culture Gram staining and (b) *Brevibacterium paucivorans* colony morphology on trypticase soy agar II containing 5% sheep blood.
Brevibacterium species including ours have been previously reported as shown in Table 2 [1–4, 10–15]. Five and 2 had hematologic or non-hematologic malignancies, and acquired immunodeficiency syndrome (AIDS) of the 12 patients, respectively. Five of the 12 (42%) had malignancies, and 2 of the 12 (17%) had AIDS. Ten of the 11 (91%) for which information is available had in-dwelling central venous catheter (CVC), including CV port. Four of the 12 were not conventional immunocompromised patients, but those who suffered from severe diseases. As for outcome, 10 of 11 (91%) patients whose information regarding the outcome is available were improved. However, 3 of the 10 (30%) patients recurred after antibiotic therapy from 13 to 28 days. These results suggest that Brevibacterium bacteremia could have a poor prognosis the same as gram-negative rods bacteremia. To underestimate these unspecific but relevant clinical symptoms and misinterpretation as apathogenic organisms could contribute result in delayed diagnosis and treatment of this emerging and mainly opportunistic pathogen. Thus, it is important to sensitize clinicians and microbiologists to this environmental pathogenic microorganism.

As for the infection site, considering the clinical course and bacteria of gram-positive rods, it is possible that this case might be caused by catheter-related bloodstream infection (CRBSI). Unfortunately, it was unclear, because a catheter culture was not obtained.

**Table 1** Antimicrobial susceptibility of *Brevibacterium paucivorans* isolated from blood culture

| Antimicrobial agents  | MIC (μg/mL) | Interpretation |
|-----------------------|-------------|----------------|
| Ampicillin            | > 0.5       |                |
| Gentamicin            | 1           | S              |
| Amikacin              | 8           |                |
| Cefazidime            | <=1         |                |
| Ceftriazone           | 2           | I              |
| Cefazolin             | 4           |                |
| Cefepime              | 2           | I              |
| Clindamycin           | > 4         | R              |
| Ciprofloxacin         | 0.25        | S              |
| Imipenem              | <=0.5       | S              |
| Levofloxacin          | <=0.25      |                |
| Rifampicin            | <=0.12      | S              |
| Vancomycin            | <=0.5       | S              |
| Daptomycin            | 0.5         | S              |
| Meropenem             | <=0.5       | S              |
| Doxycycline           | <=0.5       | S              |

MIC minimum inhibitory concentration, S susceptible, I intermediate, R resistant

*Brevibacterium* species including ours have been previously reported as shown in Table 2 [1–4, 10–15]. Five and 2 had hematologic or non-hematologic malignancies, and acquired immunodeficiency syndrome (AIDS) of the 12 patients, respectively. Five of the 12 (42%) had malignancies, and 2 of the 12 (17%) had AIDS. Ten of the 11 (91%) for which information is available had in-dwelling central venous catheter (CVC), including CV port. Four of the 12 were not conventional immunocompromised patients, but those who suffered from severe diseases. As for outcome, 10 of 11 (91%) patients whose information regarding the outcome is available were improved. However, 3 of the 10 (30%) patients recurred after antibiotic therapy from 13 to 28 days. These results suggest that *Brevibacterium* bacteremia could have a poor prognosis the same as gram-negative rods bacteremia. To underestimate these unspecific but relevant clinical symptoms and misinterpretation as apathogenic organisms could contribute result in delayed diagnosis and treatment of this emerging and mainly opportunistic pathogen. Thus, it is important to sensitize clinicians and microbiologists to this environmental pathogenic microorganism.

As for the infection site, considering the clinical course and bacteria of gram-positive rods, it is possible that this case might be caused by catheter-related bloodstream infection (CRBSI). Unfortunately, it was unclear, because a catheter culture was not obtained.
The patient died of candidemia. It might have been caused by CRBSI or bowel translocation. This patient was a particularly difficult case to manage due to multiple co-morbidities such as chronic heart failure and mild chronic kidney disease. In addition, she was super-elderly and a wheelchair user. Both the poor general condition and the clinical course including antibiotic therapy might have contributed to her candidemia.

Conclusion

Physicians and microbiologists should be aware that Brevibacterium are uncommon but important agents which could cause opportunistic infections in immunocompetent as well as immunocompromised patients.

Abbreviations

AIDS: Acquired immunodeficiency syndrome; CRBSI: Catheter-related blood stream infection; CT: Computed tomography; CVC: Central venous catheter; JCM: the Japan collection of microorganisms; MALDI-TOF-MS: Matrix-assisted laser desorption ionization time of flight; MEPM: Meropenem; MIC: Minimum inhibitory concentration

Acknowledgments

We are grateful for the diligent and thorough critical reading of our manuscript by Dr. Yoshihiro Ohikuni, Chief Physician, Taiyo and Mr. John Wocher, Executive Vice President and Director, International Affairs/International Patient Services, Kameda Medical Center (Japan).

Funding

None declared.

Availability of data and materials

All data generated during this study are included in its supplementary information file.

Authors’ contributions

NA, NN, HW, HK, AS, MH, YK, YY, HM carried out the clinical follow up. NA drafted the manuscript. NA, AY, HW, NN, DS and HS performed microbial testing and NA, NN, HW, HK, AS, MH, YK, YY, HM performed laboratory analysis. HK, AS and MH supervised the antibiotic and antiviral therapy. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this report.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 2 May 2018 Accepted: 8 April 2019
Published online: 25 April 2019

References

1. McCaughey C, Damani NN, McCaughey C, Damani NN. Central venous line infection caused by Brevibacterium epidermidis. J Inf Secur. 1991;23:211–2.
2. Lina B, Carlotti A, Lesaint V, Devaux Y, Freney J, Fleurette J. Persistent bacteremia due to Brevibacterium species in an immunocompromised patient. Clin Infect Dis. 1994;18:487–8.
3. Reinert RR, Reinert RR, Schmitzler N, Haase G, Lutticken R, Fabry U, Schaal KP, Funke G. Recurrent bacteremia due to Brevibacterium casei in an immunocompromised patient. Eur J Clin Microbiol Infect Dis. 1995;14:1082–5.
4. Wayne P.A. Clinical and Laboratory Standard Institute. Methods for antimicrobial dilution and disk susceptibility testing for infrequently isolated or fastidious bacteria; approved guideline-second edition. M45-A2, vol. 30, no. 18. Clinical and Laboratory Standard Institute, 2010.
5. Wauters G, Charlier J, Jansens M, Delmee M. Brevibacterium paucivorans sp. nov., from human clinical specimens. Int J Syst Evol Microbiol. 2001;51:1703–7.
6. Wauters G, Avesani V, Laffineur K, Charlier J, Janssens M, Van Bosterhaut B, Delmee M. *Brevibacterium lutescens* sp. nov. from human and environmental samples. Int J Syst Evol Microbiol. 2003;53:1321–5.

7. Wauters G, Haase G, Avesani V, Charlier J, Janssens M, Van Broeck J, Delmee M. Identification of a novel *Brevibacterium* species isolated from humans and description of *Brevibacterium sanguinis* sp. nov. J Clin Microbiol. 2004;42:2829–32.

8. Pascual C, Collins MD. *Brevibacterium ovium* sp. nov., isolated from poultry. Int J Syst Bacteriol. 1999;49(Pt 4):1527–30.

9. McBride ME, Ellner KM, Black HS, Claridge JE, Wolf JE. A new *Brevibacterium* sp. isolated from infected genital hair of patients with white piedra. J Med Microbiol. 1993;39:255–61.

10. Kaukoranta-Tolvanen SS, Sivonen A, Kostiala AA, Hormila P, Vaara M. Bacteremia caused by *Brevibacterium* species in an immunocompromised patient. Eur J Clin Microbiol Infect Dis. 1995;14:801–4.

11. Castagnola E, Conte M, Venzano P, Garaventa A, Viscoli C, Barretta MA, et al. Broviac catheter-related bacteraemias due to unusual pathogens in children with cancer: case reports with literature review. J Inf Secur. 1997;34:215–8.

12. Brazzola P, Zbinden R, Rudin C, Schaad UB, Heininger U. *Brevibacterium casei* sepsis in an 18-year-old female with AIDS. J Clin Microbiol. 2000;38:3513–4.

13. Oğünç D, Gültekin M, Cölak D, Timuragaoglu A, Ongüt G, Mutlu G, et al. Bacteremia caused by *Brevibacterium* species in a patient with chronic lymphocytic leukemia. Haematologia (Budap). 2010;32:151–3.

14. Beukinga I, Rodriguez-Villalobos H, Deplano A, Jacobs F, Struelens MJ. Management of long-term catheter-related *Brevibacterium* bacteraemia. Clin Microbiol Infect. 2004;10:465–7.

15. Ulrich S, Zbinden R, Pagano M, Fischler M, Speich R. Central venous catheter infection with *Brevibacterium* sp. in an immunocompetent woman: case report and review of the literature. Infection. 2006;34:103–6.